Incidence of clinically meaningful laboratory abnormalities (safety);Incidence of treatment-emergent adverse events by type, frequency, severity, and causality (safety);Incidence of serious adverse events by type, frequency, severity, and causality (safety);Time from onset of COVID-19 symptoms to treatment (Day 1);Presence and levels of anti-drug antibodies directed to COVI-AMG;Viral load as assessed using plasma and salivary samples at various timepoints;Incidence of dose-limiting toxicities (safety);Cytokine levels post-treatment;Incidence of adverse events by type, frequency, severity, and causality (safety)

Incidence of clinically meaningful laboratory abnormalities (safety);Incidence of treatment-emergent adverse events by type, frequency, severity, and causality (safety);Incidence of serious adverse events by type, frequency, severity, and causality (safety);Time from onset of COVID-19 symptoms to treatment (Day 1);Presence and levels of anti-drug antibodies directed to COVI-AMG;Viral load as assessed using plasma and salivary samples at various timepoints;Incidence of dose-limiting toxicities (safety);Cytokine levels post-treatment;Incidence of adverse events by type, frequency, severity, and causality (safety)